{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:34:40Z","timestamp":1790213680805,"version":"4.1.0"},"reference-count":24,"publisher":"BMJ","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:p>\n                  <jats:bold>Objective:<\/jats:bold> To describe the epidemiology of invasive fungal infection in very low birthweight (VLBW: &lt;1500 g) infants in the United Kingdom.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Design:<\/jats:bold> National prospective surveillance study between February 2003 and February 2004 using the British Paediatric Surveillance Unit reporting system reconciled with cases identified through routine laboratory reporting to the Health Protection Agency (England, Wales, and Northern Ireland), the Scottish Centre for Infection and Environmental Health, and the UK Mycology Reference Laboratory.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results:<\/jats:bold> Ninety four confirmed cases of invasive fungal infection were identified during the surveillance period giving an incidence of estimated annual incidence of 10.0 (95% confidence interval (CI) 8.0 to 12.0) cases per 1000 VLBW live births. Eighty one (86%) of the infants were of extremely low birth weight (ELBW: &lt;1000 g), incidence 21.1 (95% CI 16.5 to 25.7) per 1000 ELBW live births. <jats:italic>Candida<\/jats:italic> species, predominantly <jats:italic>C albicans<\/jats:italic> and <jats:italic>C parapsilosis<\/jats:italic>, were isolated in 93% of cases. Most organisms were isolated from the bloodstream and urinary tract. Death occurred in 41% of the infected infants before 37 weeks postconceptional age.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusions:<\/jats:bold> The incidence of invasive fungal infection in VLBW and ELBW infants in the United Kingdom is lower than reported in previous studies from tertiary centres in North America and elsewhere. The associated late neonatal and post-neonatal death rates are substantially higher than expected in infants without invasive fungal infection. These data may inform decisions about the evaluation and use of antifungal infection control strategies.<\/jats:p>","DOI":"10.1136\/adc.2005.082024","type":"journal-article","created":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T22:03:43Z","timestamp":1133906623000},"page":"F188-F192","source":"Crossref","is-referenced-by-count":79,"title":["Invasive fungal infection in very low birthweight infants: national prospective surveillance study"],"prefix":"10.1136","volume":"91","author":[{"given":"L","family":"Clerihew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T L","family":"Lamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Brocklehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2005,12,6]]},"reference":[{"key":"2025090503592941000_91.3.F188.1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.3.634"},{"key":"2025090503592941000_91.3.F188.2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199806000-00014"},{"key":"2025090503592941000_91.3.F188.3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.2.285"},{"key":"2025090503592941000_91.3.F188.4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.1.34"},{"key":"2025090503592941000_91.3.F188.5","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200004000-00011"},{"key":"2025090503592941000_91.3.F188.6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.106.4.712"},{"key":"2025090503592941000_91.3.F188.7","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-40008"},{"key":"2025090503592941000_91.3.F188.8","doi-asserted-by":"publisher","DOI":"10.1080\/08035250410030964"},{"key":"2025090503592941000_91.3.F188.9","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.188"},{"key":"2025090503592941000_91.3.F188.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0146-0005(03)00067-3"},{"key":"2025090503592941000_91.3.F188.11","doi-asserted-by":"crossref","unstructured":"Austin NC, Darlow B. Prophylactic oral antifungal agents to prevent systemic candida infection in preterm infants. Cochrane Database Syst Rev 2004;2.","DOI":"10.1002\/14651858.CD003478.pub2"},{"key":"2025090503592941000_91.3.F188.12","doi-asserted-by":"crossref","unstructured":"McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2003;1.","DOI":"10.1002\/14651858.CD003850.pub2"},{"key":"2025090503592941000_91.3.F188.13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/s-2007-999649","volume":"5","year":"1988","journal-title":"Am J Perinatol"},{"key":"2025090503592941000_91.3.F188.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010494"},{"key":"2025090503592941000_91.3.F188.15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/BF02282843","volume":"155","year":"1996","journal-title":"Eur J Pediatr"},{"key":"2025090503592941000_91.3.F188.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012657"},{"key":"2025090503592941000_91.3.F188.17","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199811000-00008"},{"key":"2025090503592941000_91.3.F188.18","doi-asserted-by":"crossref","unstructured":"Clerihew L, McGuire W. Systemic antifungal drugs for invasive fungal infection in preterm infants. Cochrane Database Syst Rev 2004;1.","DOI":"10.1002\/14651858.CD003953.pub2"},{"key":"2025090503592941000_91.3.F188.19","unstructured":"Johansen HK, Gotzsche PC. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2002;4."},{"key":"2025090503592941000_91.3.F188.20","doi-asserted-by":"crossref","unstructured":"Johansen HK, Gotzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database Syst Rev 2002;4.","DOI":"10.1002\/14651858.CD000239"},{"key":"2025090503592941000_91.3.F188.21","doi-asserted-by":"publisher","DOI":"10.1136\/fn.84.2.F131"},{"key":"2025090503592941000_91.3.F188.22","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199811000-00010"},{"key":"2025090503592941000_91.3.F188.23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.3.543"},{"key":"2025090503592941000_91.3.F188.24","doi-asserted-by":"crossref","unstructured":"G\u00c3\u00b8tzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev 2002;2.","DOI":"10.1002\/14651858.CD000026"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/adc.2005.082024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T10:59:39Z","timestamp":1757069979000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/adc.2005.082024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,6]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,4,21]]},"published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1136\/adc.2005.082024"],"URL":"https:\/\/doi.org\/10.1136\/adc.2005.082024","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,6]]}}}